Definitive Contract 75F40123C00197
Award Date
9/22/23
Potential Completion Date
9/29/26
Potential Value
$1.2M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Ann Arbor, MI 48109, USA
Solicitation Procedures
Two Step
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' Food and Drug Administration awarded a $797,837.04 definitive cost-no-fee contract to the Regents of the University of Michigan (doing business as the University of Michigan) for the PMWP#112 - Innovative Randomized Drug Trial Design Bayesian Analysis project. The contract, which does not have a set-aside designation, is for the development of analyses to support small-sample, sequential, multiple assignment randomized trials for the registration of a...
The Department of Health and Human Services Food and Drug Administration awarded a definitive cost-no-fee contract to the Regents of the University of Michigan for $1,482,306.00. The contract is to conduct research on the influence of raw materials, manufacturing variables, and storage conditions on the release performance of long-acting release microsphere products. The contract does not have a set-aside designation. The University of Michigan is a U.S. state government educational...
This is a $400,000.00 Firm Fixed Price Definitive Contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan. The contract is intended to advance the science of in vitro, animal model, pharmacokinetic studies, and/or real-world evidence studies to facilitate drug development, including studies focused on antimicrobial resistance and drug development for specific pathogens. This contract is not associated with a set-aside designation. The contract work...
The Food and Drug Administration (FDA) awarded a $997,608 firm-fixed-price contract to the Regents of the University of Michigan to conduct research and development on the characterization of Exparel, understanding of critical manufacturing process parameters, and characterization of drug release mechanisms in vitro and in vivo. This contract was awarded under a Broad Agency Announcement solicitation that the FDA renews annually to advance scientific knowledge in support of its mission to...
This is a $3,526,785.00 definitive, firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, doing business as the University of Michigan, for Prediction of In Vivo Performance Analysis Services. The contract has no set-aside designation. The University of Michigan is providing a range of research and development services under this contract, including developing high-performance computational models to simulate small intestine...
This is a federal contract award from the Food and Drug Administration (FDA) to the Regents of the University of Michigan (University of Michigan) for the development of a "Wireless Pharmaceutical Analysis Device (WPAD) and Computational Model to Determine In Vivo Drug Dissolution in GI Tract for Distinguishing Meaningful Product Differences and Ensuring Bioequivalence." The contract is a definitive contract with a cost-no-fee pricing type and has a ceiling value of $6,343,667.39....
This is a $75,000.00 firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, to the Regents of the University of Michigan. The contract does not have a set-aside designation. The University of Michigan is a leading public research institution that has previously held prime and subcontract awards with various federal agencies, including the Department of Veterans Affairs, to provide...
This is a non-set-aside definitive contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, a prominent U.S. state government-owned educational institution, on September 22, 2020. The $2,212,490.00 firm fixed-price contract is for a project titled "BAA SETTING PATIENT-CENTRIC QUALITY STANDARDS (PCQS) FOR MODIFIED RELEASE (MR) ORAL DRUG PRODUCTS WITH BIOPREDICTIVE IN VITRO DISSOLUTION-MODELS." The period of performance has been extended to...
The Food and Drug Administration (FDA) awarded a firm-fixed-price purchase order contract valued at $51,942.80 to the Regents of the University of Michigan to provide DNA isolation and 16S rRNA sequencing for microbiome analysis of murine (mouse) fecal samples. The contract has a period of performance through March 27, 2024. This requirement was sole-sourced to the University of Michigan, which has extensive experience providing research and development services to federal agencies including the...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $353,608 definitive contract to the Regents of the University of Michigan, which operates as the University of Michigan. This cost-no-fee contract was issued under Broad Agency Announcement 2017 and has a completion date of December 29, 2018. The contract does not have a set-aside designation. The University of Michigan is a U.S. state government entity and educational institution that has previously...